Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

[Research progress of infrapatellar fat pad derived mesenchymal stem cells in treatment of osteoarthritis].

Wang H., He H., Lu J., Wang Q.

Narrative Review on Osteoarthritis, Cartilage Damage, Chronic Inflammation, published in Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2026)
Country
China
Reported sample size
—
Source database
PubMed
PMID
42150916
DOI
10.7507/1002-1892.202601032

Abstract (original English)

To summarize research progress of infrapatellar fat pad derived mesenchymal stem cells (IFP-MSCs) in treatment of osteoarthritis (OA). The recent domestic and international literature on IFP-MSCs was reviewed. The mechanisms and latest research progress of IFP-MSCs in the treatment of OA were summarized and analyzed from aspects such as basic biological characteristics, core therapeutic mechanisms, preclinical research evidence, bioengineering strategies for optimizing therapeutic effects, and the current status of clinical studies and application. The main mechanism of IFP-MSCs for OA treatment lies in the significant paracrine effect. By releasing cytokines, exosomes, etc. , IFP-MSCs work synergistically to exert anti-inflammatory effects, protect cartilage, and promote repair. Preclinical studies have verified its efficacy and mechanism in vitro and in animal models. To promote clinical translation, researchers have developed a series of bioengineering strategies, including standardized cell preparation and functional preprocessing (such as three-dimensional culture, inflammatory factor stimulation), genetic engineering modification, exosome engineering, and the design of intelligent delivery carriers, aiming to optimize cell functions and achieve precise treatment. Preliminary clinical studies have confirmed its safety and short-term benefits in improving symptoms. Although

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansMesenchymal Stem Cell TransplantationAdipose TissueMesenchymal Stem CellsAnimalsTissue EngineeringOsteoarthritis, KneeExosomesCytokines

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research